Table 2 Patient characteristics on admission according to a three-group classification of change in Ret-He levels between admission and discharge.
From: Clinical utility of reticulocyte hemoglobin equivalent in patients with heart failure
Variable | Group 1 ΔRet-He ≦ − 2 pg (n = 17) | Group 2  − 2 pg < ΔRet-He < 2 pg (n = 36) | Group 3 2 pg ≦ ΔRet-He (n = 35) | P value |
|---|---|---|---|---|
Age (years) | 78 (74–82) | 76 (72–84) | 75 (68–82) | 0.303 |
Men, n (%) | 10 (59) | 23 (64) | 25 (71) | 0.631 |
BMI (kg/m2) | 21.4 (19.6–23.9) | 22.6 (21.0–24.9) | 24.0 (22.1–27.9) | 0.044 |
SBP (mmHg) | 131 (126–143) | 119 (109–142) | 129 (124–148) | 0.147 |
HR (bpm) | 69 (61–81) | 81 (67–98) | 85 (69–105) | 0.081 |
NYHA functional class III/IV, n | 16 (94) | 33 (92) | 34 (97) | 0.608 |
Past HF, n (%) | 8 (47) | 15 (42) | 20 (57) | 0.421 |
HT, n (%) | 16 (94) | 30 (83) | 24 (69) | 0.077 |
DM, n (%) | 6 (35) | 19 (53) | 14 (40) | 0.393 |
AF, n (%) | 4 (24) | 8 (22) | 17 (49) | 0.040 |
OMI, n (%) | 8 (47) | 11 (31) | 10 (29) | 0.381 |
CVD, n (%) | 2 (12) | 3 (8) | 5 (14) | 0.731 |
eGFR (mL/min/1.73m2) | 31 (19–50) | 51 (32–69) | 57 (38–67) | 0.077 |
LVEF (%) | 36 (27–55) | 37 (29–60) | 35 (24–51) | 0.504 |
BNP (pg/mL) | 1050 (352–2470) | 644 (426–974) | 640 (519–1390) | 0.325 |
Alb (g/dL) | 3.2 (2.9–3.9) | 3.4 (3.1–3.7) | 3.3 (3.1–3.7) | 0.563 |
Hb (g/dL) | 10.3 (8.7–10.9) | 10.7 (10.1–11.4) | 10.6 (9.5–12.0) | 0.403 |
MCV (fL) | 93.7 (88.9–98.6) | 92.6 (88.4–97.1) | 92.1 (86.4–96.0) | 0.450 |
MCH (pg) | 31.1 (30.0–33.3) | 30.6 (28.7–32.2) | 30.6 (27.7–31.4) | 0.315 |
MCHC (%) | 33.3 (32.7–33.6) | 32.8 (32.2–33.7) | 33.0 (31.5–33.7) | 0.271 |
Fe (µg/dL) | 54 (38–65) | 44 (35–62) | 34 (24–53) | 0.132 |
TIBC (µg/dL) | 235 (201–286) | 255 (232–332) | 297 (233–344) | 0.073 |
TSAT (%) | 19.2 (13.0–34.9) | 18.2 (12.5–22.8) | 11.1 (8.3–19.3) | 0.034 |
Ferritin (μg/L) | 176 (89–437) | 121 (63–228) | 79 (31–193) | 0.052 |
Ret-He (pg) | 36.6 (32.9–39.0) | 32.3 (31.1–34.2) | 31.2 (26.6–32.3) |  < 0.001 |
β-blockers, n (%) | 13 (76) | 23 (64) | 23 (66) | 0.646 |
ACE-Is/ARBs, n (%) | 10 (59) | 22 (61) | 21 (60) | 0.987 |
Ca blockers, n (%) | 10 (59) | 11 (31) | 8 (23) | 0.032 |
Loop diuretics, n (%) | 5 (29) | 20 (56) | 18 (51) | 0.191 |